Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Acquired by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 16.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 132,752 shares of the company's stock after purchasing an additional 18,955 shares during the period. Sequoia Financial Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $2,040,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at $39,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at $44,000. Compagnie Lombard Odier SCmA purchased a new stake in Teva Pharmaceutical Industries during the first quarter valued at about $54,000. Finally, Versant Capital Management Inc increased its stake in Teva Pharmaceutical Industries by 437.8% during the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after acquiring an additional 4,312 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Bank of America increased their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, UBS Group reduced their price objective on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Stock Up 2.2%

TEVA stock traded up $0.37 during trading on Wednesday, reaching $17.01. The stock had a trading volume of 8,343,532 shares, compared to its average volume of 10,241,474. The company has a current ratio of 1.03, a quick ratio of 0.74 and a debt-to-equity ratio of 2.59. The firm has a fifty day moving average price of $16.84 and a 200 day moving average price of $17.40. The company has a market capitalization of $19.50 billion, a P/E ratio of -14.80, a PEG ratio of 0.86 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. The business had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The company's revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.48 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares of the company's stock, valued at $170,012.78. The trade was a 38.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.55% of the stock is currently owned by insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.